Pacira BioSciences, Inc. has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc. Effective January 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for EXPAREL® (bupivacaine liposome injectable suspension). This collaboration is aimed at improving patient care and optimizing cost savings to healthcare organizations and will allow Premier members to access EXPAREL, a single-dose local and regional analgesic that provides prolonged postsurgical pain control while reducing reliance on opioids. Pacira and Premier share the common goals of advancing innovation, improving patient care, and pursuing value in healthcare.

This collaboration will allow Pacira to further achieve these important objectives while making a lasting impact on healthcare providers and patients across the country.